Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients

Phase 4

Completed

Conditions: Heart Transplantation

First Posted Date: 2005-09-15

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00170859

Locations: 🇩🇪
Novartis Investigational Site, Various Cities, Germany

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Phase 4

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: imatinib mesylate

First Posted Date: 2005-09-15

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT00171899

Locations: 🇨🇦
Novartis Investigative Site, Toronto, Canada

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Phase 2

Completed

Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions: Drug: STI571

First Posted Date: 2005-09-15

Last Posted Date: 2021-07-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 532

Registration Number: NCT00171223

Locations: 🇺🇸
New York Presbyterian Hospital, New York, New York, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
Dana Faber Cancer Institute, Boston, Massachusetts, United States

and more 9 locations

Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2005-09-15

Last Posted Date: 2014-02-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT00171834

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Ellis Fisher Cancer Center, Columbia, Missouri, United States
🇺🇸
Hillman Cancer Center, Pittsburg, Pennsylvania, United States

and more 1 locations

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

Phase 3

Completed

Conditions: Transfusion-dependent Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2005-09-15

Last Posted Date: 2020-02-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1784

Registration Number: NCT00171821

Locations: 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom

Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions

Phase 4

Completed

Conditions: Pain
Neoplasm Metastasis
Cancer

Interventions: Drug: Zoledronic acid in combination with therapy

First Posted Date: 2005-09-15

Last Posted Date: 2017-06-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 75

Registration Number: NCT00171964

Locations: 🇩🇪
Novartis Investigative Site, Herne, Germany

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Phase 4

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Imatinib Mesylate

First Posted Date: 2005-09-15

Last Posted Date: 2012-08-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT00171977

Locations: 🇯🇵
Novartis Investigative Site, Tokyo, Japan

A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome

Phase 2

Terminated

Conditions: Hypereosinophilic Syndrome

Interventions: Drug: imatinib mesylate

First Posted Date: 2005-09-15

Last Posted Date: 2012-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00171860

Locations: 🇧🇪
Novartis Investigative Site, Leuven, Belgium

A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates

Phase 4

Completed

Conditions: Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated

Interventions: Drug: Zoledronic acid

First Posted Date: 2005-09-15

Last Posted Date: 2012-04-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT00172016

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

Phase 3

Terminated

Conditions: Constipation Predominant
Irritable Bowel Syndrome (IBS-C)

First Posted Date: 2005-09-15

Last Posted Date: 2012-04-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT00171431

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy